
Why Black unemployment just rose to its highest level since January 2022
The jobless rate for Black Americans climbed to 6.8% in June, the Labor Department said Thursday, up sharply from May's 6% and the highest level since January 2022.
Meanwhile, the national unemployment rate ticked down to 4.1% and employers added a stronger-than-expected 147,000 jobs in June, according to Thursday's jobs report. Joblessness also declined for Whites, Hispanics and Asians.
President Donald Trump's chaotic trade war, which paralyzed business decision-making and sparked fears of higher prices, was one factor in the rise in Black unemployment. For months, businesses have said the Trump administration's significant policy changes — from on-again, off-again tariffs to cuts in federal funding — have made it difficult to plan ahead, prompting some to put hiring plans on hold, according to various surveys.
Black Americans are usually impacted first whenever the economy begins to weaken, economists say. Black Americans lag behind their White counterparts in income, wealth, financial savings and home ownership, according to previous CNN reporting. Additionally, the Trump administration has placed diversity, equity and inclusion programs in its crosshairs.
'When the economy slows down, Black workers may be impacted more quickly or more severely,' said Daniel Zhao, senior economist at Glassdoor. 'But it's consistent with the broader story for all workers of unemployment trending upwards over the last two years. We've just seen more of that for Black workers.'
And while the broader labor market seems to be chugging along, that has mostly been due to a few industries: health care, local government and hospitality.
In June, the private education and health services industry was up a remarkable 411,000 net jobs compared to six months ago, according to Labor Department data. All other industries, except government and hospitality, added fewer than 51,000 jobs each during that same period.
'Black Americans tend to work in transportation, warehousing and utilities, which are industries where we've seen hiring pulled back, especially in the last few months,' said Cory Stahle, senior economist at employment site Indeed. 'Businesses are trying to figure out what they're going to commit to as far as pricing, spending and hiring while trying to navigate these tariffs and the uncertainty.'
Black Americans may also be feeling the brunt of the Trump's administration's aggressive downsizing of the federal government, which shed 7,000 jobs last month. Federal employment is down 69,000 from January, according to the Labor Department.
'Job losses in the federal government have continued, which could be explaining part of what's going on, especially as the administration targets Diversity, Equity, and Inclusion programs,' said Jessica Fulton, senior fellow at the Joint Center for Political and Economic Studies, a nonprofit that studies the challenges facing Black Americans. 'Black Americans are more likely to work in federal government in particular.'
Zhao, Stahle and Fulton all said it's too soon to make any decisive conclusions about the economic state of Black Americans based the latest employment figures.
The household survey the Labor Department uses to calculate monthly employment figures draws from relatively small sample sizes for different racial and ethnic groups, making the numbers more prone to swings from month to month.
Despite the labor market's resilience, the economy has shown some signs of weakness in other areas. In addition to the limited job growth in most industries, consumer spending fell after tariff-induced spending sprees in the spring.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected on-time supplemental New Drug application Submission for AXS-05 in Alzheimer's Disease Agitation. According to the analyst, it has a high probability of regulatory success and may lead to a potential $900 million in sales by 2030. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. He further stated that the continued launch progress of Auvelity in major depressive disorder is another positive factor for Axsome Therapeutics, Inc. (NASDAQ:AXSM). The analyst told investors in a research note that this growth trajectory is anticipated to continue, supported by market penetration strategies and an expanded sales force. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system conditions with limited treatment options. Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
18 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.